167 related articles for article (PubMed ID: 22513979)
21. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
22. Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion.
Joshi B; Strugnell SS; Goetz JG; Kojic LD; Cox ME; Griffith OL; Chan SK; Jones SJ; Leung SP; Masoudi H; Leung S; Wiseman SM; Nabi IR
Cancer Res; 2008 Oct; 68(20):8210-20. PubMed ID: 18922892
[TBL] [Abstract][Full Text] [Related]
23. Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosine-phosphorylated caveolin-1.
Goetz JG; Joshi B; Lajoie P; Strugnell SS; Scudamore T; Kojic LD; Nabi IR
J Cell Biol; 2008 Mar; 180(6):1261-75. PubMed ID: 18347068
[TBL] [Abstract][Full Text] [Related]
24. GLUT1 glucose transporter expression in benign and malignant thyroid nodules.
Haber RS; Weiser KR; Pritsker A; Reder I; Burstein DE
Thyroid; 1997 Jun; 7(3):363-7. PubMed ID: 9226204
[TBL] [Abstract][Full Text] [Related]
25. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
[TBL] [Abstract][Full Text] [Related]
26. [The expression of galectin-3 in nodular thyroid goitre].
Chen WJ; Yu MH; Xu Y; Shen J
Zhonghua Nei Ke Za Zhi; 2006 Jun; 45(6):452-5. PubMed ID: 16831319
[TBL] [Abstract][Full Text] [Related]
27. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H
Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010
[TBL] [Abstract][Full Text] [Related]
28. Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors.
Išić T; Savin S; Cvejić D; Marečko I; Tatić S; Havelka M; Paunović I
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1805-12. PubMed ID: 20204403
[TBL] [Abstract][Full Text] [Related]
29. Hexokinase III, cyclin A and galectin-3 are overexpressed in malignant follicular thyroid nodules.
Hooft L; van der Veldt AA; Hoekstra OS; Boers M; Molthoff CF; van Diest PJ
Clin Endocrinol (Oxf); 2008 Feb; 68(2):252-7. PubMed ID: 17868400
[TBL] [Abstract][Full Text] [Related]
30. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
31. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
[TBL] [Abstract][Full Text] [Related]
32. Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms.
Matesa-Anić D; Moslavac S; Matesa N; Cupić H; Kusić Z
Acta Clin Croat; 2012 Jun; 51(2):237-41. PubMed ID: 23115948
[TBL] [Abstract][Full Text] [Related]
33. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
34. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma.
Maruta J; Hashimoto H; Yamashita H; Yamashita H; Noguchi S
Diagn Cytopathol; 2004 Dec; 31(6):392-6. PubMed ID: 15540177
[TBL] [Abstract][Full Text] [Related]
35. Surgeon-performed ultrasound can predict differentiated thyroid cancer in patients with solitary thyroid nodules.
Jabiev AA; Ikeda MH; Reis IM; Solorzano CC; Lew JI
Ann Surg Oncol; 2009 Nov; 16(11):3140-5. PubMed ID: 19655201
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic value of galectin-3 as a marker for malignancy in follicular patterned thyroid lesions.
Oestreicher-Kedem Y; Halpern M; Roizman P; Hardy B; Sulkes J; Feinmesser R; Stern Y
Head Neck; 2004 Nov; 26(11):960-6. PubMed ID: 15386597
[TBL] [Abstract][Full Text] [Related]
37. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
38. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis.
Wiseman SM; Melck A; Masoudi H; Ghaidi F; Goldstein L; Gown A; Jones SJ; Griffith OL
Ann Surg Oncol; 2008 Oct; 15(10):2811-26. PubMed ID: 18612701
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
J Cancer Res Clin Oncol; 2007 Apr; 133(4):213-8. PubMed ID: 17072649
[TBL] [Abstract][Full Text] [Related]
40. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications.
Rorive S; Eddafali B; Fernandez S; Decaestecker C; André S; Kaltner H; Kuwabara I; Liu FT; Gabius HJ; Kiss R; Salmon I
Mod Pathol; 2002 Dec; 15(12):1294-301. PubMed ID: 12481010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
